Your browser doesn't support javascript.
loading
Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
Faruqui, Atiya R; Xavier, Denis; Kamat, Sandhya K; Chandy, Sujith J; Medhi, Bikash; Tripathi, Raakhi K; Shetty, Yashashri C; Raj, John Michael; Kaushal, Sandeep; Balakrishnan, S; Atal, Shubham; Tripathi, Santanu K; Badyal, Dinesh K; Dikshit, Harihar; Roy, Sukalyan Saha; Trivedi, Niyati; Chatterjee, Suparna; Desai, Chetna; Tripathi, C D; Rege, Nirmala N; Gupta, Pooja; Raveendran, R; Kaul, Rajni; Kshirsagar, Nilima A.
Afiliação
  • Faruqui AR; Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, India.
  • Xavier D; Department of Pharmacology, St. John's Medical College, Bengaluru, Karnataka, India.
  • Kamat SK; Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
  • Chandy SJ; Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.
  • Medhi B; Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
  • Tripathi RK; Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
  • Shetty YC; Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
  • Raj JM; Department of Biostatistics, St. John's Medical College, Bengaluru, Karnataka, India.
  • Kaushal S; Department of Pharmacology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.
  • Balakrishnan S; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
  • Atal S; Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
  • Tripathi SK; Department of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India.
  • Badyal DK; Department of Pharmacology, Christian Medical College, Ludhiana, Punjab, India.
  • Dikshit H; Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, Bihar, India.
  • Roy SS; Department of Pharmacology, Indira Gandhi Institute of Medical Science, Patna, Bihar, India.
  • Trivedi N; Department of Pharmacology, Medical College Baroda, Vadodara, Ahmedabad, Gujarat, India.
  • Chatterjee S; Department of Pharmacology, Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal, India.
  • Desai C; Department of Pharmacology, B.J. Medical College, Ahmedabad, Gujarat, India.
  • Tripathi CD; Department of Pharmacology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
  • Rege NN; Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edwards Medical Hospital, Mumbai, Maharashtra, India.
  • Gupta P; Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
  • Raveendran R; Department of Pharmacology, Jawaharlal Institute of Postgraduate Education & Research, Puducherry, India.
  • Kaul R; Division of Basic Medical Sciences, New Delhi, India.
  • Kshirsagar NA; National Chair Clinical Pharmacology, Indian Council for Medical Research, New Delhi, India.
Indian J Med Res ; 153(1 & 2): 219-226, 2021.
Article em En | MEDLINE | ID: mdl-33818480
BACKGROUND & OBJECTIVES: Hydroxychloroquine (HCQ), reported to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in in vitro studies, has been recommended for prophylaxis of COVID-19 in healthcare workers (HCWs). The objective of this study was to assess short-term adverse events (AEs) of HCQ in HCWs. METHODS: This cross-sectional study among consenting HCWs taking prophylaxis and working in hospitals with COVID-19 patients used online forms to collect details of HCWs, comorbidities, prophylactic drugs used and AEs after the first dose of HCQ. Verification of dose and AEs was done by personal contact. Multivariate logistic regression analysis was done to determine the effect of age, gender and dose of HCQ on AE. RESULTS: Of the 1303 HCWs included, 98.4 per cent (n=1282) took HCQ and 66 per cent (n=861) took 800 mg as first day's dose. Among the 19.9 per cent (n=259) reporting AEs, 1.5 per cent (n=20) took treatment for AE, none were hospitalized and three discontinued HCQ. Gastrointestinal AEs were the most common (172, 13.2%), with less in older [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.35-0.89], with more in females (OR 2.46, 95% CI 1.78-3.38) and in those taking a total dose of 800 mg on day one compared to a lower dose. Hypoglycaemia (1.1%, n=14), cardiovascular events (0.7%, n=9) and other AEs were minimal. INTERPRETATION & CONCLUSIONS: HCQ prophylaxis first dose was well tolerated among HCWs as evidenced by a low discontinuation. For adverse effects, a small number required treatment, and none required hospitalization. The study had limitations of convenience sampling and lack of laboratory and electrocardiography confirmation of AEs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoal de Saúde / COVID-19 / Tratamento Farmacológico da COVID-19 / Hidroxicloroquina Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoal de Saúde / COVID-19 / Tratamento Farmacológico da COVID-19 / Hidroxicloroquina Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article